Drug Profile
Cancer vaccine NY-ESO-1 - Sanofi
Latest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Genzyme Corporation
- Developer Sanofi
- Class Cancer vaccines; Peptide vaccines; Peptides; Saponins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 29 Jul 2003 Genzyme General, Genzyme Biosurgery and Genzyme Molecular Oncology are now called Genzyme Corporation
- 03 Jul 2003 Data presented at the 39th Annual Meeting of the American Society of Clinical Oncology (ASCO-2003) have been added to the Cancer therapeutic trials section
- 02 Aug 2002 This vaccine is still in active development